Weekly injectionFDA-approved
Zepbound®
The same tirzepatide in a prefilled single-dose pen — no needle handling or priming.
Learn MorePrescription Weight Management
Real, substantial weight loss. A full month, one pen.
Tirzepatide injection · multi-dose KwikPen® · by Eli Lilly
Zepbound® KwikPen® delivers four once-weekly tirzepatide doses in a single device — with a licensed provider guiding your plan from day one.
- Clinically studied weight-loss results — see the data below
- One KwikPen, four once-weekly doses — a full month of treatment
- Provider-guided titration from 2.5 mg up to 15 mg when appropriate
Prescription only. A licensed clinician determines whether treatment is appropriate. Always read and follow the Instructions for Use supplied with your KwikPen.
1 / 4
Your Rx is ready
One pen. Four weekly doses.
Brand-name Zepbound® KwikPen®, prescribed online and shipped to your door through licensed pharmacy partners.
- Type
- GIP/GLP-1 multi-dose pen
- Frequency
- Once weekly
- Doses per pen
- 4 (one month)
- Status
- FDA-approved
- Manufacturer
- Eli Lilly
Mechanism
Two appetite-regulating pathways
Tirzepatide targets GIP and GLP-1 receptors to help curb hunger and support weight loss.
Inject once weekly
The KwikPen® delivers tirzepatide under the skin — one dose each week, four doses per pen.
Activates GIP + GLP-1 receptors
Two incretin pathways involved in appetite, fullness, and how the body handles food.
Helps you feel fuller faster and longer
Digestion slows and hunger signals quiet, so smaller portions feel natural.
Supports weight loss with diet and exercise
Alongside a reduced-calorie eating pattern and increased physical activity.
Clinical evidence
Clinically proven weight-loss support
20.9% average body-weight reduction at 15 mg in a 72-week trial (average starting weight about 231 lb), versus 3.1% with placebo. Individual results vary, and your provider chooses your dose based on response and tolerability.
15 mg maintenance dose
20.9%
average body-weight loss at 72 weeks (SURMOUNT-1 trial).*
Placebo
3.1%
average body-weight loss at 72 weeks in the same trial.*
- Once-weekly tirzepatide
- Used with diet and exercise
- FDA-approved for chronic weight management
*Average 20.9% body weight loss at 72 weeks on the 15 mg dose, versus 3.1% for placebo, based on the SURMOUNT-1 clinical trial in adults with obesity or overweight plus a weight-related condition, alongside a reduced-calorie diet and increased physical activity. Individual results vary; no specific outcome is guaranteed.
Dosing
A gradual, provider-guided schedule.
Zepbound® starts low and steps up no faster than every four weeks. Each KwikPen® is labeled for one dose strength — your provider prescribes the next strength when it's time to step up.
Starting
2.5 mg
weekly
Step 1
5 mg
weekly
Step 2
7.5 mg
weekly
Step 3
10 mg
weekly
Step 4
12.5 mg
weekly
Maximum
15 mg
weekly
Maintenance doses of 5 mg, 10 mg, or 15 mg are common. Not every patient needs the highest dose.
Using your KwikPen®
How the KwikPen® works
A six-stage routine, once a week. Your provider walks you through the first injection, and the Instructions for Use stay with your pen.
Step 1
Prepare
Wash your hands, check the label and expiration date, and confirm the medicine is clear and colorless to slightly yellow.
Step 2
Attach needle
Pull off the pen cap, wipe the rubber seal, and screw a new pen needle straight on. Remove both needle shields.
Step 3
Prime
Turn the dose knob to the prime symbol, hold the pen with the needle up, and press the dose button until you see medicine at the tip.
Step 4
Choose site
Stomach (at least 2 inches from the navel), thigh, or back of the upper arm. Rotate sites each week.
Step 5
Dial + inject
Dial to 1 for a full dose. Insert the needle, press and hold the dose button, and count slowly to 5 after the dial returns to 0.
Step 6
Remove + store
Remove and discard the needle in a sharps container. Recap the pen and store it in the refrigerator between doses.
Four device rules
- Use a new pen needle for every weekly injection.
- Never share your KwikPen® or needles with anyone else, even if the needle is changed.
- Do not use any leftover medicine after your fourth dose.
- Discard the pen 30 days after first use or after 4 doses, whichever comes first.
Your options
KwikPen® vs. single-dose pen
Same tirzepatide, same weekly schedule, same clinical evidence. The only difference is the device.
| KwikPen® | Single-dose pen | |
|---|---|---|
| Active ingredient | Tirzepatide | Tirzepatide |
| Doses per device | 4 weekly doses | 1 dose |
| Pen needles | Attach a new needle each week | Built in, hidden |
| Priming | Required before each dose | Not required |
| Storage after first use | Refrigerate; discard after 30 days or 4 doses | Single use |
| Dose strengths | 2.5–15 mg | 2.5–15 mg |
Prefer a device with no needle handling? Learn about the single-dose Zepbound® pen.
The process
From assessment to ongoing support
Personalized care, every step of the way.
1.
Complete your online visit
Share your health history and goals from the comfort of home — about 10 minutes.
2.
Provider reviews and prescribes if appropriate
A licensed provider reviews your information and creates a plan that's right for you.
3.
Transparent self-pay pricing
Your total cost is confirmed before you commit — no insurance, no surprise bills.
4.
KwikPen® shipped to your door
Brand-name Zepbound® KwikPen® ships discreetly through licensed pharmacy partners.
5.
Ongoing support to stay on track
Dose adjustments, check-ins, and real people who care.
Severe gastrointestinal reactions
Nausea, vomiting, and diarrhea can be severe, especially during dose increases. Tell your provider if symptoms don't ease.
Acute kidney injury
Vomiting or diarrhea can cause dehydration and worsen kidney function; stay hydrated.
Gallbladder disease
Gallstones and gallbladder inflammation have been reported; watch for upper-abdominal pain, fever, or yellowing of the skin.
Pancreatitis
Stop use and seek care for severe, persistent abdominal pain, with or without vomiting, that may radiate to the back.
Hypoglycemia
Risk is higher when used with insulin or sulfonylureas; know the signs of low blood sugar.
Severe allergic reactions
Stop use and get emergency help for swelling, trouble breathing, rapid heartbeat, or severe rash.
Pregnancy & medication interactions
Do not use if pregnant or planning pregnancy. Tirzepatide may reduce the effectiveness of oral contraceptives around dose increases — talk to your provider. Also report depression or suicidal thoughts and every medication you take.
Common side effects
Nausea, diarrhea, vomiting, constipation, abdominal pain, indigestion, injection-site reactions, fatigue, and decreased appetite.
Provider-guided
A short checklist before your first injection.
Your provider reviews your BMI and weight-related conditions, personal and family thyroid history, pancreatitis and gallbladder history, kidney function, current medications, pregnancy plans, and walks you through the KwikPen® Instructions for Use.
Questions
Zepbound® KwikPen® FAQ
The medication is identical — tirzepatide at the same weekly doses. The single-dose pen is used once and discarded. The KwikPen® holds four weekly doses in one prefilled device and requires attaching a new pen needle for each injection.
Once a week, on the same day each week, at any time of day, with or without food. One KwikPen® covers a full month of treatment.
Treatment starts at 2.5 mg weekly for four weeks, then increases in 2.5 mg steps (5 mg → 7.5 mg → 10 mg → 12.5 mg → 15 mg) no faster than every four weeks. Each KwikPen® is labeled for a single dose strength, so your provider prescribes a new pen strength when your dose increases.
In the SURMOUNT-1 clinical trial, adults on the 15 mg maintenance dose lost an average of 20.9% of body weight at 72 weeks, versus 3.1% for placebo, alongside diet and exercise. Individual results vary and no specific outcome is guaranteed.
Keep it in the refrigerator (36°F to 46°F) with the cap on and no needle attached. It can be kept at room temperature up to 86°F for a limited period as described in the Instructions for Use. Do not freeze.
Graceland Wellness is fully cash-pay with transparent self-pay pricing confirmed before you commit — no insurance, no copays, no surprise bills. Medication ships directly to your door through licensed pharmacy partners.
Nausea, diarrhea, vomiting, constipation, abdominal pain, indigestion, injection-site reactions, fatigue, and decreased appetite. These are most noticeable during dose increases and often ease with time. Serious risks are described in the safety section above.
Explore more treatments
Other FDA-approved weight-management options
Weekly injectionFDA-approved
Wegovy® pen
Semaglutide, a GLP-1-only injection with a higher-dose HD option for eligible patients.
Learn MoreDaily tabletFDA-approved
Wegovy® pill
The same semaglutide molecule in a once-daily oral tablet — no needles.
Learn MoreGet started
A full month of treatment, one pen at a time.
Take a private assessment and a licensed provider will tell you whether Zepbound® KwikPen® — or another option — fits your history, routine, and goals.
Prescription required. Zepbound® and KwikPen® are registered trademarks of Eli Lilly and Company; Wegovy® is a registered trademark of Novo Nordisk A/S. Graceland Wellness is not affiliated with either manufacturer. Transparent self-pay pricing; medication ships directly to your door.